OBJECTIVE:Childhood-onset schizophrenia (COS) is a rare but severe form of the disorder, which is often treatment refractory. Short-term studies have indicated a greater differential efficacy, evident through effect sizes, favoring clozapine over other agents in alleviating negative symptoms in COS patients compared with adult-onset patients (AOS). There have been no data for COS patients on long-term compliance with clozapine treatment. Therefore, we wanted to know, over a span of up to 24 years, how many of our COS cohort had remained on clozapine for at least 2 years. We review short-term treatment data and present updated long-term data on compliance and functioning for our patients. METHODS: We present the results for long-term medication maintenance over a 24 year observation period for our cohort of 131 patients. Of this cohort, 91.6% (120) were available for follow-up information from either in-person or telephone contact with the patient and/or family members. We defined clozapine compliance as ≥2 years receiving this medication and doing well. RESULTS: We were able to contact 120 of the 131 patients. In spite of the additional cost and inconvenience of regular blood monitoring, 87 patients (72.5%, 87/120) adhered to long-term clozapine maintenance therapy with dosages ranging from 50 to 900 mg, and a median dosage of 500 mg. This rate exceeds the long-term clozapine maintenance rates reported for AOS patients. CONCLUSIONS: Short-term data on differential efficacy and long-term maintenance data suggest a possibly greater efficacy of clozapine, relative to other antipsychotics, in COS than in AOS. Our overall findings indicate that very early-onset schizophrenic patients may be more responsive to clozapine. This extends other support for clozapine as an option in the treatment of early-onset schizophrenia.
RCT Entities:
OBJECTIVE: Childhood-onset schizophrenia (COS) is a rare but severe form of the disorder, which is often treatment refractory. Short-term studies have indicated a greater differential efficacy, evident through effect sizes, favoring clozapine over other agents in alleviating negative symptoms in COS patients compared with adult-onset patients (AOS). There have been no data for COS patients on long-term compliance with clozapine treatment. Therefore, we wanted to know, over a span of up to 24 years, how many of our COS cohort had remained on clozapine for at least 2 years. We review short-term treatment data and present updated long-term data on compliance and functioning for our patients. METHODS: We present the results for long-term medication maintenance over a 24 year observation period for our cohort of 131 patients. Of this cohort, 91.6% (120) were available for follow-up information from either in-person or telephone contact with the patient and/or family members. We defined clozapine compliance as ≥2 years receiving this medication and doing well. RESULTS: We were able to contact 120 of the 131 patients. In spite of the additional cost and inconvenience of regular blood monitoring, 87 patients (72.5%, 87/120) adhered to long-term clozapine maintenance therapy with dosages ranging from 50 to 900 mg, and a median dosage of 500 mg. This rate exceeds the long-term clozapine maintenance rates reported for AOSpatients. CONCLUSIONS: Short-term data on differential efficacy and long-term maintenance data suggest a possibly greater efficacy of clozapine, relative to other antipsychotics, in COS than in AOS. Our overall findings indicate that very early-onset schizophrenicpatients may be more responsive to clozapine. This extends other support for clozapine as an option in the treatment of early-onset schizophrenia.
Authors: Robert R Conley; Deanna L Kelly; Charles M Richardson; Carol A Tamminga; William T Carpenter Journal: J Clin Psychopharmacol Date: 2003-12 Impact factor: 3.153
Authors: K McKenna; C T Gordon; M Lenane; D Kaysen; K Fahey; J L Rapoport Journal: J Am Acad Child Adolesc Psychiatry Date: 1994-06 Impact factor: 8.829
Authors: R F Asarnow; K H Nuechterlein; D Fogelson; K L Subotnik; D A Payne; A T Russell; J Asamen; H Kuppinger; K S Kendler Journal: Arch Gen Psychiatry Date: 2001-06
Authors: S Kumra; J A Frazier; L K Jacobsen; K McKenna; C T Gordon; M C Lenane; S D Hamburger; A K Smith; K E Albus; J Alaghband-Rad; J L Rapoport Journal: Arch Gen Psychiatry Date: 1996-12
Authors: Istvan Bitter; Martin R K Dossenbach; Shlomo Brook; Peter D Feldman; Stephen Metcalfe; Carlo A Gagiano; János Füredi; György Bartko; Zoltan Janka; Csaba M Banki; Gabor Kovacs; Alan Breier Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2004-01 Impact factor: 5.067
Authors: C T Gordon; J A Frazier; K McKenna; J Giedd; A Zametkin; T Zahn; D Hommer; W Hong; D Kaysen; K E Albus Journal: Schizophr Bull Date: 1994 Impact factor: 9.306
Authors: Herbert Y Meltzer; William V Bobo; Ajanta Roy; Karu Jayathilake; Yuejin Chen; Aygun Ertugrul; A Elif Anil Yağcioğlu; Joyce G Small Journal: J Clin Psychiatry Date: 2008-02 Impact factor: 4.384
Authors: Jerome H Taylor; Scott Appel; Matthew Eli; Aaron Alexander-Bloch; Lawrence Maayan; Raquel E Gur; Michael H Bloch Journal: J Child Adolesc Psychopharmacol Date: 2020-07-01 Impact factor: 2.576